博拓生物(688767) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥103,685,805.87, representing a decrease of 89.81% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2023 was ¥11,899,389.65, down 97.58% year-over-year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,055,122.92, a decline of 98.13% compared to the previous year[10]. - Basic earnings per share for Q1 2023 were ¥0.11, down 97.62% from the same period last year[6]. - The company reported a net profit of CNY 1,723,502.30 in Q1 2023, down from CNY 6,684,565.40 in Q1 2022[20]. - The net profit for Q1 2023 was ¥11,502,242.39, a significant decrease from ¥493,587,345.24 in Q1 2022, reflecting a decline of approximately 97.67%[21]. - The total operating income for Q1 2023 was ¥13,671,180.79, compared to ¥581,192,726.47 in Q1 2022, indicating a decrease of about 97.65%[21]. - The total comprehensive income for Q1 2023 was ¥12,210,106.37, down from ¥493,573,794.84 in Q1 2022, marking a decline of approximately 97.53%[21]. Cash Flow - The net cash flow from operating activities was -¥20,061,528.63, reflecting a decrease of 102.88% year-over-year[10]. - The cash flow from operating activities showed a net outflow of ¥20,061,528.63 in Q1 2023, contrasting sharply with a net inflow of ¥696,516,794.88 in Q1 2022[24]. - The total cash inflow from operating activities in Q1 2023 was ¥120,899,027.45, compared to ¥1,357,734,415.90 in Q1 2022, reflecting a decrease of approximately 91.10%[23]. - The total cash outflow from operating activities in Q1 2023 was ¥140,960,556.08, down from ¥661,217,621.02 in Q1 2022, indicating a decrease of about 78.73%[24]. - The cash flow from investing activities showed a net outflow of ¥9,292,153.48 in Q1 2023, compared to a net outflow of ¥36,326,849.89 in Q1 2022[24]. - The company reported a decrease in tax payments, with ¥10,020,530.98 in Q1 2023 compared to ¥47,225,529.56 in Q1 2022, a reduction of approximately 78.77%[24]. Research and Development - The total R&D investment amounted to ¥9,880,272.83, a reduction of 49.56% compared to the previous year[6]. - The proportion of R&D investment to operating revenue increased by 7.60 percentage points to 9.53%[6]. - Research and development expenses decreased to CNY 9,880,272.83, a reduction of 49.53% compared to CNY 19,586,991.87 in the same period last year[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,729,306,540.87, a decrease of 0.80% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to CNY 2,729,306,540.87, a decrease from CNY 2,751,217,156.02 at the end of 2022[18]. - Total liabilities decreased to CNY 154,799,346.12 from CNY 188,920,067.64 at the end of 2022, reflecting a reduction of 18.06%[18]. - The company's equity attributable to shareholders increased to CNY 2,573,796,024.20 from CNY 2,561,259,556.96 at the end of 2022[18]. Market Demand - The company attributed the significant decline in revenue and profit primarily to a sharp decrease in market demand for COVID-19 testing products[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,297[13].